Summary
Liothyronine Sodium has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypothyroidism would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypothyroidism. ClinicalTrials.gov lists 8 registered trials linking Liothyronine Sodium to Hypothyroidism: 2 are currently recruiting; 4 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT05682482). It plans or enrolled 600 participants. Registration activity spans 2006 to 2024. No published literature item is linked to Liothyronine Sodium and Hypothyroidism in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Hypothyroidism ranks 81 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Hashimoto's (most common cause) is irreversible in majority; spontaneous recovery in <5%; subclinical hypothyroidism spontaneously normalizes in ~30-40% of cases within 2 years without treatment.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 41.5 (trials 21.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 0 active / not yet recruiting, 4 completed, 2 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05682482 | LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism. 2022 | recruiting | Phase 3 | 600 |
| NCT01800617 | A Study of T3 Therapy in Patients With Hypothyroidism 2013 | completed | Phase 2 | 18 |
| NCT04782856 | Energy Metabolism in Thyroidectomized Patients 2020 | completed | Phase 2 | 13 |
| NCT05015725 | The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients 2021 | completed | Not applicable | 262 |
| NCT03926585 | Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment 2019 | completed | Not applicable | 82 |
| NCT06731764 | Novel Approaches to the Treatment of Hypothyroidism 2024 | recruiting | PHASE2, PHASE3 | 90 |
| NCT00488644 | Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors 2006 | terminated | Not applicable | 12 |
| NCT06353555 | Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage 2023 | status unknown | Not applicable | 100 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Liothyronine Sodium approved for Hypothyroidism?
Liothyronine Sodium has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypothyroidism would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypothyroidism. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Liothyronine Sodium in clinical trials for Hypothyroidism?
ClinicalTrials.gov lists 8 registered trials linking Liothyronine Sodium to Hypothyroidism: 2 are currently recruiting; 4 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT05682482). It plans or enrolled 600 participants. Registration activity spans 2006 to 2024.
What does the evidence show for Liothyronine Sodium in Hypothyroidism?
Liothyronine Sodium has 4 completed registered trials for Hypothyroidism but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.